Sutro Biopharma Inc (STRO)
2.51
-0.02
(-0.79%)
USD |
NASDAQ |
Nov 22, 16:00
2.52
+0.01
(+0.40%)
After-Hours: 20:00
Sutro Biopharma Net Income (Quarterly): -48.79M for Sept. 30, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
Date | Value |
---|---|
September 30, 2024 | -48.79M |
June 30, 2024 | -48.02M |
March 31, 2024 | -58.21M |
December 31, 2023 | 31.06M |
September 30, 2023 | -49.28M |
June 30, 2023 | -38.52M |
March 31, 2023 | -50.05M |
December 31, 2022 | -34.59M |
September 30, 2022 | -19.49M |
June 30, 2022 | -26.01M |
March 31, 2022 | -39.11M |
December 31, 2021 | -38.12M |
September 30, 2021 | -30.90M |
June 30, 2021 | -6.152M |
March 31, 2021 | -30.36M |
Date | Value |
---|---|
December 31, 2020 | -59.54M |
September 30, 2020 | 17.14M |
June 30, 2020 | 29.87M |
March 31, 2020 | -19.60M |
December 31, 2019 | -14.79M |
September 30, 2019 | -12.91M |
June 30, 2019 | -13.79M |
March 31, 2019 | -14.25M |
December 31, 2018 | -1.493M |
September 30, 2018 | -10.24M |
June 30, 2018 | -11.54M |
March 31, 2018 | -12.05M |
December 31, 2017 | -15.34M |
September 30, 2017 | -1.418M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-59.54M
Minimum
Dec 2020
31.06M
Maximum
Dec 2023
-26.67M
Average
-32.75M
Median
Net Income (Quarterly) Benchmarks
Fulcrum Therapeutics Inc | -21.70M |
NovaBay Pharmaceuticals Inc | -1.212M |
Palatin Technologies Inc | -7.824M |
iBio Inc | -3.989M |
Theriva Biologics Inc | -7.726M |
Net Income (Quarterly) Related Metrics
Revenue (Quarterly) | 8.52M |
Total Expenses (Quarterly) | 76.44M |
EPS Diluted (Quarterly) | -0.59 |
Enterprise Value | -181.28M |
Profit Margin (Quarterly) | -572.6% |
Earnings Yield | -64.14% |
Normalized Earnings Yield | -71.81 |